[go: up one dir, main page]

CL2009001682A1 - Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). - Google Patents

Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).

Info

Publication number
CL2009001682A1
CL2009001682A1 CL2009001682A CL2009001682A CL2009001682A1 CL 2009001682 A1 CL2009001682 A1 CL 2009001682A1 CL 2009001682 A CL2009001682 A CL 2009001682A CL 2009001682 A CL2009001682 A CL 2009001682A CL 2009001682 A1 CL2009001682 A1 CL 2009001682A1
Authority
CL
Chile
Prior art keywords
staurosporine
benzoyl
pharmaceutical composition
oral administration
bioavailability
Prior art date
Application number
CL2009001682A
Other languages
English (en)
Inventor
Graham Paul Matthews
Barbara Haberlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001682(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2009001682A1 publication Critical patent/CL2009001682A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad; uso del compuesto en la elaboración de un medicamento.
CL2009001682A 1999-02-16 2009-07-31 Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). CL2009001682A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds

Publications (1)

Publication Number Publication Date
CL2009001682A1 true CL2009001682A1 (es) 2010-07-23

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001682A CL2009001682A1 (es) 1999-02-16 2009-07-31 Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).

Country Status (34)

Country Link
US (3) US20020061873A1 (es)
EP (1) EP1152750B1 (es)
JP (2) JP5057610B2 (es)
KR (2) KR20080064914A (es)
CN (1) CN100367930C (es)
AR (2) AR022589A1 (es)
AT (1) ATE430554T1 (es)
AU (1) AU765776B2 (es)
BR (1) BRPI0008228B8 (es)
CA (1) CA2362277C (es)
CL (1) CL2009001682A1 (es)
CZ (1) CZ303979B6 (es)
DE (1) DE60042151D1 (es)
DK (1) DK1152750T3 (es)
EC (1) ECSP083351A (es)
ES (1) ES2326783T3 (es)
GB (1) GB9903547D0 (es)
HK (1) HK1045807B (es)
HU (1) HUP0105364A3 (es)
ID (1) ID30504A (es)
IL (3) IL144512A0 (es)
MY (1) MY128362A (es)
NO (1) NO331232B1 (es)
NZ (1) NZ513529A (es)
PE (1) PE20001499A1 (es)
PL (1) PL198330B1 (es)
PT (1) PT1152750E (es)
RU (1) RU2266121C2 (es)
SI (1) SI1152750T1 (es)
SK (1) SK286967B6 (es)
TR (1) TR200102385T2 (es)
TW (1) TWI240636B (es)
WO (1) WO2000048571A1 (es)
ZA (1) ZA200106677B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
CN100350911C (zh) * 2001-03-26 2007-11-28 诺瓦提斯公司 含有水溶性差的活性成分、表面活性剂和水溶性聚合物的药物组合物
CZ299756B6 (cs) 2001-05-16 2008-11-12 Novartis Ag Kombinace s obsahem N-{5-[4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylfenyl}-4-(3-pyridyl)-2-pyrimidin-aminu k lécení proliferativních onemocnení
MXPA04004137A (es) * 2001-10-30 2005-01-25 Novartis Ag Derivados de estauroesporina como inhibidores de la actividad de cinasa de tirosina del receptor flt3.
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003254566A1 (en) * 2002-07-23 2004-02-09 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
AU2007284615B2 (en) * 2006-08-16 2011-10-27 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
NZ600999A (en) * 2009-12-22 2014-06-27 Leo Pharma As Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
WO2013042069A1 (en) * 2011-09-22 2013-03-28 Ariel-University Research And Development Company, Ltd. Emulsions and methods of making emulsions
KR20190032265A (ko) * 2015-12-09 2019-03-27 포스파제닉스 리미티드 약제학적 제형
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (es) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
ES2136620T3 (es) 1991-04-19 1999-12-01 Lds Technologies Inc Formulaciones de microemulsiones convertibles.
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
PT589843E (pt) * 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
AU692506B2 (en) 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US5599808A (en) 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions
EP0763041A1 (en) * 1994-06-01 1997-03-19 Novartis AG Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733358A3 (de) * 1995-03-21 1998-05-20 Novartis AG Intravenös applizierbare Nanosuspensionen
WO1998013032A1 (en) 1996-09-27 1998-04-02 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
ES2229473T3 (es) * 1997-01-30 2005-04-16 Novartis Ag Composiciones farmaceuticas sin aceite que contienen ciclosporina a.
CN1208047C (zh) 1997-07-29 2005-06-29 法玛西雅厄普约翰美国公司 亲脂性化合物的自体乳化剂
PL192080B1 (pl) 1997-07-29 2006-08-31 Upjohn Co Kompozycja farmaceutyczna zawierająca związek piranonowy
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
US8722664B2 (en) 2014-05-13
JP2012111763A (ja) 2012-06-14
NO20013964D0 (no) 2001-08-15
ID30504A (id) 2001-12-13
SK286967B6 (sk) 2009-08-06
KR20080064914A (ko) 2008-07-09
HUP0105364A2 (hu) 2002-05-29
CZ20012931A3 (cs) 2001-11-14
ES2326783T3 (es) 2009-10-20
US20080070897A1 (en) 2008-03-20
DE60042151D1 (de) 2009-06-18
TWI240636B (en) 2005-10-01
TR200102385T2 (tr) 2002-09-23
SI1152750T1 (sl) 2009-10-31
CZ303979B6 (cs) 2013-07-31
US20140056974A1 (en) 2014-02-27
BRPI0008228B8 (pt) 2021-05-25
PT1152750E (pt) 2009-08-07
ECSP083351A (es) 2008-08-29
AU3154200A (en) 2000-09-04
HK1045807A1 (zh) 2002-12-13
CA2362277C (en) 2010-03-30
KR20010093281A (ko) 2001-10-27
JP2002537242A (ja) 2002-11-05
DK1152750T3 (da) 2009-08-24
NO20013964L (no) 2001-10-15
BRPI0008228B1 (pt) 2016-08-23
CA2362277A1 (en) 2000-08-24
CN1339963A (zh) 2002-03-13
IL144512A (en) 2011-03-31
EP1152750B1 (en) 2009-05-06
PE20001499A1 (es) 2001-01-12
AR022589A1 (es) 2002-09-04
HUP0105364A3 (en) 2003-02-28
ATE430554T1 (de) 2009-05-15
AU765776B2 (en) 2003-10-02
NO331232B1 (no) 2011-11-07
MY128362A (en) 2007-01-31
ZA200106677B (en) 2003-01-14
IL144512A0 (en) 2002-05-23
IL192666A0 (en) 2009-02-11
AR082579A2 (es) 2012-12-19
CN100367930C (zh) 2008-02-13
NZ513529A (en) 2003-10-31
SK11722001A3 (sk) 2001-12-03
RU2266121C2 (ru) 2005-12-20
WO2000048571A1 (en) 2000-08-24
JP5057610B2 (ja) 2012-10-24
GB9903547D0 (en) 1999-04-07
US20020061873A1 (en) 2002-05-23
KR100880859B1 (ko) 2009-01-30
US8575147B2 (en) 2013-11-05
HK1045807B (zh) 2008-12-05
EP1152750A1 (en) 2001-11-14
PL198330B1 (pl) 2008-06-30
BR0008228A (pt) 2001-10-30
PL350556A1 (en) 2002-12-16

Similar Documents

Publication Publication Date Title
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
BR0015188A (pt) Composições farmacêuticas
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
ITFI930247A1 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
ATE189400T1 (de) Knochenwachstumsfördernde zusammensetzung
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
AR022252A1 (es) Composicion de administracion oral.
BG104620A (en) Oral pharmaceutical extended release dosage form
SE8804629D0 (sv) New therapeutically active compounds
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
HRP20020428B1 (en) Bicyclic amino acids as pharmaceutical agents
IS1664B (is) Ný aðferð við að framleiða útskipt 4-fenýl-4-píperídínkarboxamíð sem hefur bæði staðbundin deyfandiog kvalastillandi áhrif
AR012417A1 (es) COMPOSICIoN FARMACÉUTICA DE ADMINISTRACIoN ORAL Y PROCEDIMIENTO PARA SU PRODUCCION.
ES2160145T3 (es) Composicion farmaceutica para la administracion oral de flavonoides.
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz